evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,783 questions · 10,022 findings · 882 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,100 · 21%GRADE not reported 1,013 · 10.1%Very low 2,237 · 22.3%Low 2,514 · 25.1%Moderate 1,709 · 17.1%High 449 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Pressure‐garment therapy (PGT) vs silicone

Scar improvement (POSAS) (0–10, higher score = more severe scarring) · people with burn wounds likely to develop hypertrophic scarring
2 findings from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Overall survival (OS) · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Progression‐free survival · newly‐diagnosed EOC

It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).

1 finding from 1 review

Chemotherapy with bevacizumab followed by bevacizumab maintenance vs chemotherapy alone

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

Chemotherapy with bevacizumab followed by maintenance bevacizumab probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).

1 finding from 1 review

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

Overall response rate (ORR), · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant immunotherapy (high dose interferon) plus chemotherapy changes overall response rate (ORR), measured after 8 weeks of treatment and… compared with neoadjuvant chemotherapy (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy vs placebo (maintenance therapy)

Adverse events (grade ≥ 3) · newly‐diagnosed EOC

It is very uncertain whether summary of findings table ‐ Newly‐diagnosed EOC: PARPi monotherapy changes any severe adverse event (grade 3 or higher) (G3+ SevAE ) compared with placebo (maintenance therapy) (very low certainty).

1 finding from 1 review